Arvinas, Inc. (NASDAQ:ARVN) Short Interest Up 7.0% in January

Arvinas, Inc. (NASDAQ:ARVN) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 10,440,000 shares, a growth of 7.0% from the January 15th total of 9,760,000 shares. Based on an average daily volume of 885,500 shares, the short-interest ratio is currently 11.8 days.

Arvinas Trading Up 3.6 %

Shares of ARVN opened at $18.31 on Tuesday. The business’s fifty day moving average is $18.75 and its 200 day moving average is $23.10. Arvinas has a 12-month low of $16.61 and a 12-month high of $53.08.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. During the same quarter last year, the firm earned ($2.53) EPS. On average, equities research analysts expect that Arvinas will post -3.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ARVN has been the subject of a number of analyst reports. Oppenheimer lifted their target price on shares of Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Wedbush reissued an “outperform” rating and issued a $57.00 price objective on shares of Arvinas in a research report on Tuesday, February 11th. BTIG Research began coverage on Arvinas in a research report on Tuesday, December 10th. They set a “buy” rating and a $69.00 target price on the stock. Barclays decreased their target price on Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a report on Friday, February 7th. Thirteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Arvinas currently has an average rating of “Buy” and a consensus price target of $60.00.

Institutional Trading of Arvinas

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARVN. Vanguard Group Inc. boosted its position in shares of Arvinas by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company’s stock valued at $135,389,000 after buying an additional 56,561 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Arvinas by 6.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company’s stock valued at $78,656,000 after acquiring an additional 249,295 shares in the last quarter. RTW Investments LP boosted its holdings in Arvinas by 19.8% during the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company’s stock worth $63,919,000 after acquiring an additional 551,979 shares during the last quarter. FMR LLC grew its stake in shares of Arvinas by 7.6% in the 3rd quarter. FMR LLC now owns 2,883,604 shares of the company’s stock worth $71,023,000 after acquiring an additional 204,317 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Arvinas by 18.7% in the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock valued at $57,371,000 after purchasing an additional 367,343 shares during the last quarter. 95.19% of the stock is owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.